Skip to Content
Merck
  • The effect of inhaled inactived Mycobacterium phlei as a treatment for asthma.

The effect of inhaled inactived Mycobacterium phlei as a treatment for asthma.

Molecular medicine reports (2016-12-31)
Moyu Ming, Chaoqian Li, Zhixi Luo, Shengqiu Lv, Qixiang Sun
ABSTRACT

Allergic asthma is a chronic airway disorder characterized by airway inflammation, mucus hypersecretion, and airway hyperresponsiveness (AHR). A murine model of asthma was used to examine the antiasthmatic effect of inhaled inactived Mycobacterium phlei (M. phlei). AHR, neutrophil levels, eosinophil levels and levels of interleukin (IL)‑17 and IL‑23 receptor (IL‑23R) were monitored. The results demonstrated that inactivated M. phlei alleviates the IL‑17+γδT cell‑mediated immune response and attenuates airway inflammation and airway hyperresponsiveness in the asthmatic murine lung, partially through inhibiting the expression of IL‑23R. In conclusion, inactivated M. phlei may be an effective antiasthmatic treatment, regulating IL‑17‑producing γδT (IL‑17+γδT) cell‑mediated airway inflammation and airway hyperresponsiveness to relieve the symptoms of mice with asthma.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-IL-23R Antibody, cytoplasmic, from rabbit, purified by affinity chromatography
SKU
Pack Size
Availability
Price
Quantity